[5]Khreish, Fadi et al. “225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience.” European journal of nuclear medicine and molecular imaging vol [6]Kratochwil, Clemens et al. “Targeted ...
225Ac-PSMA617 for Therapy of Prostate Cancer – Where Do We Stand? - ScienceDirectdoi:10.1016/j.jmir.2019.03.060Prof. Alfred MorgensternJournal of Medical Imaging and Radiation Sciences
225Ac-PSMA-617 for PSMA-Targeted a-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer 喜欢 0 阅读量: 102 作者: Apostolidis,Christos,Verburg,Frederik,A.,Bruchertseifer,Frank,Kopka,Klaus,Morgenstern 展开 摘要: Prostate-specific membrane antigen (PSMA) is a pro 展开 关键词...
225Ac-PSMA is one of the novel theragnostic alpha endoradiotherapy agents under investigation for salvage therapy in metastatic castration resistant prostate cancer (mCRPC). We present a case of hormone naïve patient with high-volume metastatic, symptomatic prostate cancer involving the lungs. The ...
Over recent years, [225Ac]Ac-PSMA and [177Lu]Lu-PSMA radiopharmaceutical therapy have evolved as a promising treatment option for advanced prostate cancer. Especially for alpha particle emitter treatments, there is still a need for improving dosimetry, which requires accurate values of relative biolo...
et al. 225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer. J. Nucl. Med. 57, 1941–1944 (2016). Article CAS Google Scholar Jiang, Z., Revskaya, E., Fisher, D. R. & Dadachova, E. In vivo evaluation of free and chelated ...
此外,早在2013年FDA就批准了拜耳公司的氯化镭[223Ra]注射液(商品名Xofigo)用于转移性去势抵抗的前列腺癌(metastasized castration-resistant prostate cancer,mCRPC)治疗。 177Lu标记的PSMA-617靶向治疗mCRPC也是一种有希望的放射配体治疗,有很好的疗效和安全性,可以延长患者的无进展生存期和总生存期,并很快进入Ⅲ期临床...
Therapeutic efficacy of 225Ac-PSMA-617 targeted alpha therapy in patients of metastatic castrate resistant prostate cancer after taxane-based chemotherapy Article 31 May 2021 177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessmen...
177Lu-Labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy J. Nucl. Med. (2016) L. Emmett et al. Lutetium-177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion ...
225Ac-PSMA617 for Therapy of Prostate Cancer – Where Do We Stand?doi:10.1016/j.jmir.2019.03.060Alfred MorgensternElsevier BV